Cediranib (AZD2171) is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3, c-KIT, and platelet-derived growth factor receptors. Studies show cediranib to be generally well tolerated as monotherapy at doses of 45 mg/d or less. MW: 450.51. Purity ≥98%